[This review was originally posted at the Nieman Journalism Lab Glucophage Cost, on July 13, 2012.]

Evaluating newspapers' various strategies: Several wide-ranging strategies in the newspaper industry have been making headlines lately (Newhouse's draconian cuts in New Orleans, Warren Buffett's aggressive newspaper purchases, outsourcing hyperlocal news to Journatic), and The New York Times' David Carr tied a lot of them together in a sharp column identifying the severe financial difficulties facing the newspaper industry. The piece of news he reported was the fact that pension funds at major newspaper chains like Gannett and McClatchy are underfunded by hundreds of millions of dollars. Gannett Blog's Jim Hopkins said that finding deserves some attention.

One of the most prominent responses to these financial threats has been the implementation of online paywalls, a strategy that eByline's Peter Beller reported is more common at larger papers, to the point where it now affects a third of America's daily newspaper readers, buy Glucophage online no prescription. Closely tied to that strategy is a doubling-down by publishers on "original reporting" online, which media analyst Frederic Filloux contended is a losing proposition, because aggregators' tech- and marketing-savviness are trumping the quality of traditional publishers' work in the battle for online readers. British journalist Adam Tinworth said part of the problem is that publishers are trying out and pitching new digital strategies far too often, instead of being patient enough to see one through, Glucophage Cost.

Here at the Lab, Where can i find Glucophage online, Ken Doctor responded to all the hand-wringing with a list of reasons for hope in the news industry, including the potential in digital circulation, the growth of tablets, community blogs, and customer data.

Elsewhere, where can i order Glucophage without prescription, media analyst Alan Mutter categorized three strategies for newspapers dealing with the new digital environment — keeping up the status quo as long as possible ("farming" it), accepting print's decline and extracting as much money as possible before it finally goes ("milking" it), and leveraging old media resources to aggressively invest in digital innovation ("feeding" it). He mapped a different publisher to each approach — Buffett to farming, Online buying Glucophage, Newhouse to milking, and Rupert Murdoch to feeding — and ultimately endorsed Murdoch's plan.

Peter Kirwan of The Media Briefing also praised Murdoch's efforts to turn up the pressure on his print properties to start making money through digital innovation: Some of the experiments might backfire, he said, but "whatever it takes, speeding up the pace of digital transition can only be a good thing."

—

Newhouse's detractors and defenders: One of those newspapers has drawn particular attention over the past month or so — the New Orleans Times-Picayune, buy Glucophage from canada, which has now undergone its drastic layoffs and plans to cut down its publishing three days a week this October. Glucophage Cost, This week, the Newhouse family, which owns the paper, rejected a request by several New Orleans bigwigs to sell the paper to an unnamed buyer whom they have reportedly lined up. One local court also moved its public notices from the TP to the weekly paper the Gambit, and the paper is also receiving rants from its reporters about its poor website.

Newhouse's moves continue to draw strong criticism from media observers, Online buy Glucophage without a prescription, including former newspaper editor John L. Robinson, who attributed the changes to the fundamental conflict between public service and profits. "Profit trumps readers every time. The owners may appreciate the public service journalism the paper may produce, but it isn’t what they value the most," he wrote. And former Baltimore Sun reporter and "The Wire" creator David Simon argued in the Gambit that what's being lost in newspapers' evisceration is the public accountability provided by beat reporting, Glucophage from mexico.

But Newhouse has its defenders, too, including Digital First CEO John Paton, who argued that while the company is handling the transition poorly, it's still making the type of difficult, digitally centered change that's necessary for the business to survive, Glucophage Cost. GigaOM's Mathew Ingram concurred. Rem Rieder of the American Journalism Review acknowledged that arduous change is necessary for newspapers, but said the clumsiness with which Newhouse has handled its moves in New Orleans has swallowed up its goodwill and set the cause of change back.

—

Two studies with good news for mobile news: Two studies with interesting implications for digital news were released this week, Glucophage class, one on mobile news consumption and the other an international study on digital and mobile news consumption. The first, conducted by the Reynolds Journalism Institute, found that users of large tablets (i.e. Glucophage Cost, iPads and the like, rather than Kindle Fires) were older, more likely to pay for digital news, and particularly enjoyed reading on the tablet compared with other media. Poynter's Jeff Sonderman noted that those results makes "tablet readers seem the best hope for print publishers that want to make a digital transition based on paid content."

Slate's Will Oremus echoed that idea, though he cautioned that tablets may do more to eat into evening news' audience than help the traditional publishing industry, Glucophage without a prescription. This study was the final part of a three-part study on mobile media, and Amy Gahran of the Knight Digital Media Center gave some suggestions for future mobile news research, including focusing on community news in particular.

The second study, Ordering Glucophage online,  issued by Oxford's Reuters Institute, looked at digital news use in the U.S. and four European countries, with findings focusing on the rise of smartphones and tablets, as well as young people's changing news consumption habits. PaidContent's Robert Andrews highlighted the increasing willingness to pay for news among young smartphone and tablet owners, Glucophage Cost. J-prof Alfred Hermida dug into the numbers and pointed out that while the use of social media for news is up sharply, Glucophage for sale, it's driven by a small core of heavy news sharers.

—

Does outsourcing have a place in local news?: Last week's controversy regarding fake bylines at the hyperlocal content provider Journatic continued to generate debate this week, especially for newspaper columnists who defended the value of locally produced news (such as, say, Glucophage reviews, the news that appears in their newspaper). WNPR public radio hosted a discussion on outsourcing local news, and while former Patch editor-in-chief Brian Farnham didn't defend Journatic (he said it "gives me a cheap feeling"), he did say the overwhelming nitpicking and self-criticism coming from within journalism makes it difficult for any digital journalism initiative to survive.

Danish j-prof Rasmus Kleis Nielsen argued that with news' business model collapsing, the question isn't whether some aspects should be outsourced, cheap Glucophage no rx, but what and when. Glucophage Cost, If this episode illustrates that the article is untouchable, though, the scale of news production is going to have to decline, he said. "Cottage production works for the few, I don’t see how it will work for the many."

—

Reading roundup: No big stories this week, but lots of smaller ones to keep up with:

— Some continued discussion about CNN's (and others') Supreme Court reporting fiasco: The New Republic's Amy Sullivan urged journalists to stop caring about scoops, and reporters responded by defending the importance of speed in news. Sullivan replied that it's not really about speed per se, but obsession with being first with information that will become widely distributed almost immediately anyway. Poynter's Craig Silverman pulled some lessons for newsrooms from the fiasco. Buy cheap Glucophage, — Next Issue Media, a digital media joint venture among several top media companies, issued its iPad edition, which allows subscribers to read all they want of 39 magazines for a flat monthly fee — what Shawn King of The Loop and others called the Netflix model for magazines. Time's Harry McCracken said its audience will probably be limited to print magazine junkies, and GigaOM's Mathew Ingram was skeptical of the plan as a way to emulate print reading experiences, Glucophage long term.

— A group of media moguls met this week in California to talk about a variety of issues, one of which was the defeat this winter of their SOPA/PIPA anti-piracy laws. The New York Times and Forbes have more details about how that fight between media and tech is progressing, and Bloomberg broke down some of the other issues the executives would be discussing.

— The New York Observer's Kat Stoeffel reported that News Corp.'s money-losing tablet news publication, The Daily, has been placed "on watch," to be evaluated (and possibly killed) after November's election. Business Insider's Henry Blodget said The Daily has failed because it failed to carve out a niche or a distinct perspective.

— A few thought-provoking pieces that deserve a read this week: Two from the Columbia Journalism Review on making freelancing sustainable in the digital world and on the battle over the network nightly newscasts, and one here at the Lab by Jonathan Stray on getting ourselves out of like-minded "filter bubbles" in our online information consumption.

Similar posts: Lipitor Cost. Cephalexin No Rx. Buy Retin A No Prescription. Armour results. Synthroid price, coupon. Armour price, coupon.
Trackbacks from: Glucophage Cost. Glucophage Cost. Glucophage Cost. Glucophage trusted pharmacy reviews. Glucophage canada, mexico, india. After Glucophage.

[This review was originally posted at the Nieman Journalism Lab Glucophage Dosage, on June 22, 2012.]

Microsoft's unknown but intriguing tablet: Yet another company made its jump into the tablet market this week, but this was a more formidable competitor than most: Microsoft unveiled its new Surface tablet PC with precious little information, though the keyboard-cover and Windows 8 operating system got some critics' attention. Reaction from analysts was generally mixed (you can see a good variety at Engadget and the Guardian) — many were intrigued and encouraged by what they saw so far, but wanted to know more before they formed a verdict.

The big question for many observers was whether Surface might finally present a legitimate competitor for the iPad. Reuters talked to experts who said it's too soon to tell (especially since we don't know its price yet),  and The New York Times' David Pogue argued that Microsoft has an uphill battle to fight, particularly because of how far behind Apple it's starting. Order Glucophage online c.o.d, The Times' Sam Grobart, however, said Microsoft may be gunning more for the ultra-light notebook computing market than the touch-screen tablet market.

Mat Honan of Gizmodo said Surface's keyboard will be the key to challenging the iPad and Macbook Air's dominance in those areas, and Dutch entrepreneur Max Huijgen asserted that the keyboard finally moves tablets from consumption to creation devices, Glucophage Dosage. The Verge's Joshua Topolsky said Surface could fit perfectly between the iPad and the laptop, but it'll depend on price and how many developers they can get to create apps for it.

Several others noted that this week's announcement marked a significant shift for Microsoft — from software developer to hardware producer. Microsoft has ventured into hardware before (most notably with its mp3 player Zune), but as All Things D's Ina Fried pointed out, buy generic Glucophage, this is a much more important venture. Slate's Farhad Manjoo argued that the Surface seems to be a much more thought-out venture into hardware than the Zune. He and Dan Frommer Glucophage Dosage,  of SplatF were excited that Microsoft is finally taking quality hardware into its own hands, as Frommer said: "it sure looks like a better strategy for Microsoft than only trusting the Samsungs of the world to design great Windows tablets, and only trying to generate mobile revenue from Windows sales."

Meanwhile, the Columbia Journalism Review's Ryan Chittum took the opportunity to chastise the tech press for its fawning coverage of product announcements, saying they're acting more like an infomercial audience than journalists.

—

Blogging, big ideas, and 'self-plagiarism': One of nonfiction writing's young stars was discovered to be repeatedly reusing his own work this week, raising some questions about the relationship between journalism, Glucophage blogs, blogging, and trading in "big ideas." Jonah Lehrer, who was recently hired by The New Yorker, was discovered to have borrowed much of the material for his first several New Yorker blog posts from earlier pieces. Jim Romenesko first uncovered the repetition in one post, and it was quickly found in each of his others, as New York magazine documented.

Edward Champion of Reluctant Habits soon found several re-used passages in Lehrer's most recent book, is Glucophage addictive, and more serious issues cropped up as well: Romenesko and Poynter's Andrew Beaujon noted cases in which Lehrer had made it sound like he had gathered information directly when they had in fact come from secondhand sources. All of Lehrer's New Yorker posts now contain editor's notes, and Lehrer has apologized. While his editor at The New Yorker said he "understands he made a serious mistake," it appears he won't be fired.

Much of the discussion around Lehrer centered on just how serious of a mistake he had made, and why it might have happened, Glucophage Dosage. Gawker's Hamilton Nolan argued that even if he's not cheating himself with his copying, he's cheating his employer, Rx free Glucophage, who's not paying him to recycle old material. Jack Shafer of Reuters made a similar point, but noted that certain types of republication are a pretty established part of journalistic practice. Poynter's Kelly McBride talked about how the practice cheats the audience.

As for why Lehrer might have done this, Gawker's Nolan concluded that Lehrer simply "doesn't know how to do journalism" and said that while he might consider himself just a purveyor of ideas, The New Yorker is very much a journalistic publication. Slate's Josh Levin posited that Lehrer's "big ideas" stock and trade isn't compatible with blogging Glucophage Dosage, , because while big ideas are rare and have to be wrung dry, blogging requires constant streams of fresh insight. At the Columbia Journalism Review, herbal Glucophage, Felix Salmon said "big ideas" blogging can indeed be done — by iterating ideas, using links as shorthand, riffing on what you're reading, and interacting with peers.

Others objected to the term "self-plagiarism" to describe what Lehrer did — the Washington Post's Erik Wemple, Reuters' Shafer, Glucophage photos, and the New York Times' Phil Corbett, via Poynter. And Poynter's Craig Silverman pointed out how catching plagiarists (or serial repeaters) has become something of a game in itself.

—

Debating the value of print in New Orleans: The aftermath of the New Orleans Times-Picayune's cuts continued this week, as the paper published another optimistic message to readers about its future, this one from its publisher, Ricky Mathews. Ryan Chittum of the Columbia Journalism Review criticized Mathews for not mentioning the paper's massive layoffs, and Poynter's Steve Myers reported on the efforts of readers and advertisers to provide for laid-off reporters and convince Advance to rethink its print cuts, Glucophage Dosage.

Poynter's Rick Edmonds agreed with those readers and former staffers, fast shipping Glucophage, breaking down the numbers and arguing that there isn't much of a business case for cutting print editions of the paper. Instead, he said, "The move only makes financial sense as the occasion for dumping many well-paid veterans and drastically slashing news investment" — which is how the paper appears to be using it.

The University of Colorado's Steve Outing defended the decision to cut print editions, arguing that an investment into mobile media by the TP could keep readers just as informed as with a seven-day print edition. Online Glucophage without a prescription, Poynter adjunct Jason Fry came down in the middle, saying that while he's not opposed to cutting print in general, New Orleans is the wrong place — and Advance's strategy the wrong way — to do it.

—

Glucophage Dosage, Two paywalls up, one down: News organizations (and newspapers in particular) continue to put up paywalls at a steady pace — this week, we got an announcement from one of Australia's largest newspaper companies, Fairfax Media, that it would put up a paywall and cut 1,900 jobs at its publications, two of which, the Sydney Morning Herald and The Age, will merge newsrooms. Poynter's Andrew Beaujon summarized the situation, and former Age editor Andrew Jaspan explained Fairfax's decline and sounded a warning regarding the concentration of Australian media in the hands of a few moguls.

Warren Buffett's longest-held newspaper, The Buffalo News, also announced plans for a paywall, Glucophage overnight. Beaujon has the details, and The New York Times' Christine Haughney examined the News for clues to Buffett's style of newspaper management. Elsewhere, however, the New York Post (a Rupert Murdoch paper) dropped the pay plan for its iPad version, and the Online Journalism Review's Robert Niles made the case against paywalls and urged newspapers to focus solely on the unique value they can provide.

—

A new set of news innovators: The Knight Foundation announced the winners of the first round of this year's Knight News Challenge, the first year of its new three-times-a-year incarnation, Glucophage Dosage. About Glucophage, Here are the six winners, all based on the theme of networks: Behavio, a collective mobile data-sharing service (Lab profile, Techcrunch profile); PeepolTV, a livestreamed video collection project; Recovers.org, a disaster recovery organization (Lab profile); Tor Project, an open-source anonymity-aiding initiative (Lab profile); Signalnoi.se, a tool to help newsrooms understand how information moves through social networks (Lab profile, Glucophage pharmacy, Journalism.co.uk profile); and Watchup, a video news iPad app (Lab profile).

Mathew Ingram of GigaOM saw in the winners the importance of mobile media, video, and large-scale data collection, while the Lab's Joshua Benton said he feels the overall quality of applications was up this year. Buy Glucophage without a prescription, The foundation also announced the creation of the Knight Prototype Fund, which is intended as a smaller-scale, quicker way of funding innovative news projects. The Lab's Justin Ellis profiled the fund, while the MIT Center for Civic Media published an interview with two of its principals.

—

Reading roundup: Here are the other stories folks in the news-tech world were talking about this week:

— The New York Times announced a partnership Glucophage Dosage,  with BuzzFeed to collaborate on coverage of this year's political conventions, particularly through video. The Washington Post's Erik Wemple looked at what it means for the Times and BuzzFeed, and The Atlantic's Megan Garber said you can expect BuzzFeed's lolcattiest tendencies to be toned down.

— WikiLeaks' Julian Assange sought asylum in the Ecuadorian embassy in London as an attempt to avoid extradition to Sweden on sex crime accusations, Glucophage gel, ointment, cream, pill, spray, continuous-release, extended-release. Doing so was apparently a breach of his bail terms, but Salon's Glenn Greenwald defended Assange's right to seek asylum. Former WikiLeaks staffer James Ball looked at where things currently stand with the Assange drama.

— Information Architects' Oliver Reichenstein proposed a strikethrough "mark as error" function on Twitter as an alternative to deleting erroneous tweets, Glucophage Dosage. Poynter's Craig Silverman and GigaOM's Mathew Ingram voiced their support for the idea, and Journalism.co.uk asked editors for their thoughts on it. Twitter, Glucophage pictures, meanwhile, did introduce an option to view profiles without replies.

— In the most recent of several thoughtful pieces on how to improve journalism education that have been published lately, Howard Finberg advised j-schools to look to large-scale, online education to train tomorrow's journalists, and j-prof Jeff Jarvis sketched a few ideas for such a plan. J-prof Carrie Brown-Smith did counter, however, that j-schools' current skills education has value because an alarming number of students come in with such poor grasp of basic skills.

— Finally, two smart pieces to read this weekend: Here at the Lab, Jonathan Stray wrote about the inherent difficulties in designing filtering algorithms, and at Poynter, PolitiFact's Bill Adair urged journalists to supplant the news story as the basic form of journalism.

Similar posts: Purchase Synthroid. Synthroid Cost. Lipitor No Rx. Glucophage from canadian pharmacy. Where can i buy cheapest Flagyl online.
Trackbacks from: Glucophage Dosage. Glucophage Dosage. Glucophage Dosage. Order Glucophage no prescription. Glucophage dangers. No prescription Glucophage online.

[This review was originally posted at the Nieman Journalism Lab Synthroid Mg, on June 15, 2012.]

Since there was no review last week, this review is covering two weeks.

Big cuts in the Big Easy: Three weeks after news of the New Orleans Times-Picayune's cutback to three-day-a-week publication broke, the other shoe dropped this week, as Advance Publications laid off about 200 of the paper's employees, including almost half the newsroom. About 400 employees at Advance's Alabama papers were let go, too, making it one of the largest rounds of layoffs in recent American newspaper history. Poynter's Steve Myers has a great link-filled survey of the carnage, online buying Synthroid hcl, while The New York Times' Campbell Robertson portrayed the scene in New Orleans.

The people of New Orleans were, needless to say, not pleased, and they expressed their disapproval of Advance in a variety of ways. A group of major local businesses and civic organizations formed to try to stop the changes to the paper, Synthroid forum, and several major TP advertisers signed on. A "Save Our Picayune" rally drew hundreds, and the nonprofit New Orleans news org The Lens captured the deep connection between the city's residents and its paper in a photo essay, while Poynter's Julie Moos examined the story behind it, Synthroid Mg.

Advance responded to the protests by saying it wouldn't back down from its plans and publishing a thoughtful column on the roots of the paper's changes, but it was also facing criticism from outside the city as well. The American Journalism Review's Rem Rieder criticized Advance for burying the news of its layoffs while trumpeting a positive video to readers about their coming changes. Jason Berry of The Nation gathered a variety of expert opinions, including "This is a breathtaking gamble" and “This is one of the dumbest decisions by any newspaper publisher ever."

Advance is modeling the online transition of the TP and its Alabama papers after its former newspaper in Ann Arbor, Michigan, a decision that has brought quite a bit of disdain, order Synthroid no prescription. Mary Morgan, publisher of another online news org in that city, the Ann Arbor Chronicle, described what she saw as a superficial approach to its community. Synthroid Mg, At the Atlantic, John McQuaid said Advance's online strategy is more focused on gathering clicks than doing comprehensive journalism, and at the Columbia Journalism Review, New Orleanian Harry Shearer said Advance is taking a cookie-cutter approach to journalism. Fortune's Dan Mitchell agreed, saying, Japan, craiglist, ebay, overseas, paypal,  "Advance's decision isn't an investment in the digital future -- it's simply proof that Advance wants to squeeze every nickel it can out of the operation as quickly as possible." CJR's Ryan Chittum made a similar point, expressing his disappointment that the paper is gutting its newsroom and moving to a "hamster-wheel" approach online.

The Lab's Adrienne LaFrance looked to a different model — Detroit, whose two newspapers cut daily delivery down to three days a week in 2009. She looked at the differences between the two cities and also addressed the possibility that people simply won't miss the print paper.

—

The futures of print and paywalls: The discussion about the Times-Picayune also bled into a couple of bigger debates about where the news industry is (or should be) headed. The largest one focused on what role print media should have in newspapers' future, as both the New York Times and American Journalism Review ran features focusing on the potential benefits and dangers for newspapers in moving to a digital-centric approach, Synthroid Mg. The Times looked in particular at the hamster-wheel effect of chasing pageviews in a digital-first context, while AJR looked at the possible importance of targeting niches and experimenting with different models, Synthroid cost.

GigaOM's Mathew Ingram argued that doing digital journalism makes news organizations just another voice and doing it well costs lots of money, so if you're shifting primarily as a cost-cutting move (as Advance seems to be), you shouldn't expect to retain your authoritative voice. The Guardian's Roy Greenslade disagreed about the nature of authority online, but agreed that publishers are seeing the move to digital as a cost-cutting measure rather than a way to aggressively move journalism forward.

Reuters' Jack Shafer put the issue in a different way, Where can i buy Synthroid online, describing newspapers "liquidating their goodwill" — by raising prices, cutting delivery days, and shedding reporting costs — as a way of trying to extract money out of their properties before their useful life is up. Synthroid Mg, The news execs cheapening their products might protest that they're still pouring investment into their papers, Shafer said, but "if you’re winding your company down with no strategy to wind it up, you’re burning goodwill even if you don’t acknowledge it." Ingram seized on that point and urged newspaper execs to have a real plan for digital reinvention.

The other debate that flowed out of the mess in New Orleans regarded paywalls, stemming from David Simon's May Columbia Journalism Review post arguing that failures like the Times-Picayune's will continue occurring until newspapers start charging for online content. Poynter's Andrew Beaujon gave some highlights of the long discussion in the comments of that piece, and The Batavian's Howard Owens responded with a comprehensive CJR post of his own listing 10 arguments against news paywalls. CJR blogger Ryan Chittum took up Simon's cause, Synthroid coupon, issuing a response to each of Owens' points. At the Harvard Business Review, Justin Fox said it really doesn't matter what Advance and other newspapers do — the industry has been doomed for a while, and Advance is just trying to get out in front of the collapse.

—

Apple and Facebook vs, Synthroid Mg. Google: Apple held another product release announcement this week, and, Buying Synthroid online over the counter, as usual, the tech press went ga-ga over it. If you're an Apple geek, you probably already know all the details, but if you want to gorge yourself on specs, features, and screenshots, Techmeme has everything you need, buy generic Synthroid. The big new product was Apple's iOS 6, the new platform on which the iPhone, iPad, and iPod will eventually run. TechCrunch has a good rundown of its features, as well as a few quick thoughts. Synthroid Mg, As part of its announcement, Apple introduced a new laptop, gave an update on its new desktop operating system Mountain Lion, and unveiled an iOS 6 feature called Passbook that integrates all kinds of passes and tickets. Synthroid australia, uk, us, usa, (It did not, however, open up Apple TV to outside developers, as some had expected.)

One particularly interesting announcement was the deep integration of Facebook into iOS 6, including quick sharing, Siri integration, and sharing from the App Store and Game Center. Josh Constine of TechCrunch said Apple seems to be borrowing Facebook's social graph rather than trying to do social tech itself, Synthroid interactions, and The Next Web's Drew Olanoff said Apple's new side-by-side display of Facebook and Twitter functions could lead users to see Facebook as the superior network. CNET's Larry Dignan, on the other hand, saw the Facebook integration as an oversharing nightmare waiting to happen.

There were relatively few big-picture reflections on the announcements: Tech blogger John Gruber saw an anti-Google tint to the proceedings, and Business Insider laid out the ways Apple is going after Google's products and "trying to make the web irrelevant." And here at the Lab, Online Synthroid without a prescription, Josh Benton had a few takeaways for news orgs, including advice to prepare for people to expect to talk to your app and the use of Passbook for news org membership models.

—

Making curation count: A little update on the ongoing conversation surrounding online curation and aggregation of content: It flared up a couple of weeks ago after a speaker was quoted as saying that curation was "replacing creation as a form of self-expression." That set off The Awl's Choire Sicha, who said curation was an awful, arrogant word for something that's actually just collecting other people's creative work as part of a secondary market, Synthroid Mg. Editor Erin Kissane and Pocket's Mark Armstrong both defended the practice of curation (if not the term itself) and advised a collaborative approach to improving it as a technique and as a business model.

Poynter's Andrew Beaujon summarized the discussion, tying it to a satirical post by the Washington Post's Michael Cavna. On the practical level, the Lab's Justin Ellis described how one curator, Dan Shanoff, Synthroid pictures, was able to turn his hand-picked sports aggregation site Quickish into something valuable (it was bought this week by Gannett), and Digital First Media's Steve Buttry and Mandy Jenkins outlined their vision for the news curation team they're hiring.

—

Reading roundup: Bunches of smaller stories and and discussions bubbling up over the past couple of weeks. Synthroid Mg, Here's a quick summary:

— In a significant case for the TV and online video industries, the U.S. Department of Justice is investigating several cable companies for possible antitrust violations in limiting online video use by the broadband Internet customers as a way to keep people from cutting the cord on cable. The story was first reported by the Wall Street Journal, and Mike Masnick of Techdirt laid out the government's case, Buy Synthroid online cod, which he says is a good one. Fortune, GigaOM and All Things D have analyses of what this might mean for consumers. In a related development, YouTube's head talked about the possibility of selling paid subscriptions to its videos.

— The social activism-focused magazine GOOD, launched in 2006, laid off most of its staff two weeks ago. The publication's executives reportedly wanted to become "a Reddit for social good," though they denied that characterization, Synthroid Mg. The laid-off staffers are going to produce one last magazine issue together, Synthroid natural, and they're calling it Tomorrow. Poynter's Andrew Beaujon and The Atlantic's Alexander Abad-Santos have good postmortems on what went wrong at GOOD.

— The Chicago Tribune reported that its owner, the Tribune Co., is close to emerging from bankruptcy after three and a half years there, and Ad Age reported that the company would probably sell some of its major assets, including the Tribune and the Los Angeles Times. Reuters' Jack Shafer looked at the possible futures of the Tribune Co.'s papers, and it wasn't pretty. Synthroid Mg, — Warren Buffett continues to dive deeper into the newspaper industry, buying up a 3.2% stake in the Lee Enterprises newspaper chain  as well as a small daily paper in Texas. Buffett explained his strategy to Howard Kurtz of The Daily Beast, and Andrew Beaujon of Poynter pitted that strategy against Advance's web-based one.

— AOL survived a fight from some of its major investors who believe that the hyperlocal journalism model they've pursued with Patch is a fatally flawed one, as Bloomberg Businessweek's Felix Gillette outlined. AOL had some positive numbers to throw at them this week, as Patch has posted its best traffic numbers ever.

— Finally, a couple of the many thought-provoking pieces posted over the past couple of weeks: The Lab's Adrienne LaFrance examined newsrooms' attitude toward innovation through the lens of the hypothetical (or maybe not so hypothetical!) "smart refrigerator strategy." And Arizona State j-prof Tim McGuire delivered his manifesto on the state of journalism and what news organizations should and shouldn't be doing in a rapidly changing media environment.

Similar posts: Purchase Retin A. Order Cephalexin. Buy Zoloft No Prescription. Armour for sale. Where can i buy Cephalexin online. Synthroid without prescription.
Trackbacks from: Synthroid Mg. Synthroid Mg. Synthroid Mg. About Synthroid. Buy Synthroid online cod. Buy Synthroid from mexico.

[This review was originally posted at the Nieman Journalism Lab Order Synthroid, on June 1, 2012.]

Debating the meaning of Facebook’s IPO flop: Facebook’s fall following its initial public offering two weeks ago continued this week, with shares dropping under $30 (they were initially offered at $38). Several other social media-based companies have seen their stock tank, too, prompting Forbes’ Dee Gill to wonder if Facebook’s IPO has been a reminder that “even a wildly popular product won’t save a company that can’t make money.”

David Strom of ReadWriteWeb did point out, though, that stock prices soon after tech IPOs haven’t been a very reliable indicator of companies’ prospects for long-term success. The New York Times’ Joe Nocera made a similar point, arguing that Facebook’s IPO flop was fueled by get-rich-quick investors and that long-term investors should be undeterred, Synthroid treatment.

At PandoDaily, Farhad Manjoo made the case that Facebook’s IPO was a valuable corrective to a dangerously overhyped tech market: “Facebook’s IPO proves that there isn’t an endless supply of bigger suckers. And because bigger suckers are the primary ingredients in bubbles, it now seems likely that the new tech bubble—if there ever was one—is dead, dead, dead.” And The Atlantic’s Alexis Madrigal made a pretty thorough defense of Facebook’s value as a company, Synthroid forum, reminding us that it has a still-growing near-monopoly and tremendous potential for making money from its millions of users.

There was still plenty of criticism of Facebook floating around this week, though, Order Synthroid. The New York Times’ Ross Douthat saw Facebook as a sign of the lack of financial progress brought by the Internet economy, and Facebook’s advertising shortcomings continued to be a point of discussion. Ad Age reported that GM pulled its advertising from Facebook in part because Facebook balked at its proposal to run full-page ads, which, according to media consultant Terry Heaton, illustrated the difference between Madison Avenue’s philosophy of bending the masses to their will and Facebook’s gentler approach. The Huffington Post’s Bianca Bosker also looked at the tension Facebook is facing between its advertisers and users, Synthroid maximum dosage.

Here at the Lab, Dan Kennedy extended the ad problem to journalists, proposing a few ideas for adapting to an online world in which the value of ads continues to shrink. Order Synthroid, Also on the news front, Buzzfeed’s John Herrman wrote about how coverage on Twitter of the Facebook IPO indicates that Twitter is well ahead of Facebook in covering and developing breaking stories.

Another major note on Facebook to keep an eye on: The New York Timesreported that the company is trying again to build a smartphone to release later this year. It’s had several false starts in this area before, but is moving “deeper into the process” this time. Is Synthroid addictive, Facebook was also reported this week to be buying the facial recognition company Face.com.

 

The impact of New Orleans’ move away from print: As we moved into the second week of discussion of the New Orleans Times-Picayune’s cutback from daily newspaper production, the conversation began to shift from New Orleans in particular to the future of the newspaper industry as a whole. Poynter’s Steve Myers looked at a couple of the immediate issues — concerns over whether Advance Publications’ other papers (such as the Cleveland Plain Dealer) might make similar cuts, and whether New Orleans readers are likely to follow their paper online, Order Synthroid.

The New York Times’ David Carr, who broke the story, wrote a kind of elegy for the paper, concluding that while the cutback may make some financial sense, it’s a great loss for a historically corrupt city. “The constancy of a paper, ordering Synthroid online,” he wrote, “is a reminder to a city that someone is out there watching.” At the Huffington Post, Harry Shearer thought Carr wasn’t harsh enough in his assessment of Advance’s plans, arguing that breaking readers’ daily newspaper habits is foolish, not economical. Shearer, Synthroid wiki,  Myers, and Iowa journalist Dave Schwartz all pointed out that New Orleans has particularly low Internet penetration rates (not to mention high newspaper penetration rates), with Schwartz calling those without web access “casualties in a revolution.”

Mathew Ingram of GigaOM and CUNY prof Jeff Jarvis, on the other hand, both argued that we need to get past our fixation with print journalism, using it when it’s profitable but feeling free to drop it when it’s not. “We have to make print beside the point,” Jarvis wrote, Synthroid without prescription. Will Bunch of the Philadelphia Daily News, meanwhile, proposed some ideas at Poynter for resolving the journalism crisis in New Orleans, focusing on philanthropic efforts to improve Internet access, hyperlocal journalism, and accountability journalism. Al Jazeera discussed the future of the newspaper industry Order Synthroid,  in light of New Orleans’ move away from daily with a few luminaries as well. Synthroid dangers,

Cuts, layoffs, and the viability of paywalls: The Times-Picayune isn’t the only paper making these kinds of changes — Postmedia, Canada’s largest newspaper chain, announced this week it would cut the Sunday edition at three of Canada’s largest newspapers, lay off dozens of employees, and consolidate some of its editing operations, and also hinted at cutting back print days for its largest paper, Synthroid images, the National Post. Postmedia was also reported to be moving ahead with paywalls at several of its papers.

While Postmedia CEO Paul Godfrey complained in an interview with the Globe & Mail that its ad revenue was being stolen by foreign digital companies (read: Google, AOL, etc.), GigaOM’s Mathew Ingram said the problems for Postmedia and other newspapers run much deeper than cuts and paywalls. Synthroid street price, Crain’s Chicago Business also reported that the Chicago Tribune is considering a paywall potentially focusing on niche coverage, and Poynter’s Steve Myers pointed out that the major newspaper companies that aren’t charging for news are quickly becoming the outliers.

The paywall debate got a shot in the arm this week in the aftermath of the Times-Picayune’s cuts, when The Wire creator and former newspaper reporter David Simon asserted at the Columbia Journalism Review that “the whole industry will continue to collapse until everyone swallows hard and goes behind a paywall.”The short post spurred a feisty comment thread as well as several varying responses, Order Synthroid. A post at the news startup Circa made a distinction between charging for content (OK) and information (much more difficult to do), and Will Bunch made his aforementioned philanthropically driven proposals for New Orleans as a middle way between paywall advocates and detractors.

In addition, former newspaper editor John L. Robinson argued that if young people won’t even pay much for Facebook, they sure won’t pay for a newspaper — and that should worry newspaper publishers, Synthroid class. Here at the Lab, Ken Doctor added some practical approaches to the discussion, looking at the effectiveness of different newspapers’ plans to shift from advertiser revenue toward reader revenue.

Breaking down the article Order Synthroid, : We got a reprise of the occasionally occurring discussion about better ways to do the news article this week, starting with NYU professor Jay Rosen’s complaint that a Reuters article on Facebook’s IPO was too dense for non-investors to understand. That triggered a lengthy Twitter conversation between Rosen, Reuters’ Anthony De Rosa and Felix Salmon, and CUNY professor Jeff Jarvis — Storified by De Rosa — about ways to better incorporate background information into news stories. Synthroid trusted pharmacy reviews, Rosen has done plenty of thinking about this problem in the past, and this time, Jarvis expanded the Twitter discussion into a post of his own in which he reconceived the news article as a group of assets (data, background information, leads, etc.) that could be broken down, rearranged, or specialized in by various news organizations, order Synthroid from United States pharmacy, with links as the core element tying them together. “The end result is still an inverted pyramid — a prioritized set of assets that one can stop going through when one feels sated with information. But everyone’s pyramid can be different. And what fills those pyramids can come from various sources,”he wrote.

Mathew Ingram of GigaOM echoed the idea, and meanwhile, Technically Philly’s Sean Blanda and blogger Dave Winer both wrote on rethinking the elements of an article — Blanda proposed thinking of the basic unit of journalism as the fact rather than the article, and Winer said we need to do better than Wikipedia when it comes to background information and explainers, Order Synthroid.

Reading roundup: Lots of little stories and debates popping up at the intersection of news and tech this week. Here’s a few of them:

— WikiLeaks’ Julian Assange lost his appeal to the British Supreme Court against extradition to Sweden on accusations of a pair of 2010 sexual abuse cases. No prescription Synthroid online, He has two weeks to appeal one of the ruling’s points, but it looks as though he’s headed to Sweden to stand trial. Here’s The Guardian’s and The New York Times’ coverage, and Micah Sifry’s examination of the state of online whistleblowing as WikiLeaks struggles.

— A couple of ebook notes: Amazon settled its dispute Order Synthroid,  with a publisher that pulled its books from the site earlier this year, and meanwhile, two other publishers filed responses to the Department of Justice’s antitrust suit on ebook pricing, and Apple filed its response to a parallel class-action suit.

— Web designer Oliver Reichenstein ripped the ubiquitous “Share” buttons all over news and other sites, while the Lab’s Joshua Benton provided some initial data showing they may be quite helpful for news orgs to prompt sharing of their content on Twitter.

— Cornell prof Tarleton Gillespie wrote an interesting post exploring whether we can trust Twitter’s Trending Topics algorithm, and GigaOM’s Mathew Ingram said it’s not necessarily Twitter’s job to broaden our worldview, Synthroid dose, but instead our own responsibility.

— Some additional commentary on Warren Buffett’s purchase of dozens of small Media General papers two weeks ago: NYU prof Clay Shirky thinks it’s a bad idea, and Mathew Ingram agrees with him.

— Finally, it’s not shameless self-promotion if it’s actually really good: The Lab ran several fascinating pieces this week that are worth a look — Justin Ellis’ talk with Guardian editor Alan Rusbridger, some cool ideas for improving news from MIT Media Lab students courtesy of Andrew Phelps, and the AP’s Jonathan Stray’s smart column on broadening our concept of what journalists do. Enjoy.

Similar posts: Tramadol Cost. Glucophage Over The Counter. Diflucan Dosage. Bactrim price. Tramadol without a prescription. Tramadol overnight.
Trackbacks from: Order Synthroid. Order Synthroid. Order Synthroid. Buy Synthroid online cod. Synthroid pharmacy. Is Synthroid safe.

[This review was originally posted at the Nieman Journalism Lab Cephalexin Dosage, on May 25, 2012.]

Facebook’s quick fall: A week ago, Facebook had just launched the largest, most buzzworthy initial public offering in years. And now, that IPO has already brought them a potentially massive lawsuit and a federal investigation. Aside from the whole “pocketing millions upon millions of dollars” thing, it’s been a brutal week for Facebook execs. Here’s what happened.

Facebook dominated the conversation online last week (GigaOM has a good roundup from last Friday’s IPO), and a lot of that wasn’t positive, kjøpe Cephalexin på nett, köpa Cephalexin online. As data from Pew’s Project for Excellence in Journalism showed, much of the chatter online, particularly on Twitter, was about Facebook as an overhyped (and overvalued) stock, Cephalexin Dosage. Those online observers may have been more right than they knew: As reports from Reuters, Business Insider (two posts), and The Wall Street Journaldetailed, Facebook was allegedly telling top investors they had overestimated their projected financial figures, all while publicly talking up their earning potential and even expanding their stock offering to the rest of us. The result, My Cephalexin experience, so far, has been a U.S. Securities and Exchange Commission investigation and a (potentially class-action) lawsuit from investors.

There were a number of good analyses of what went wrong — at The Guardian, Heidi Moore laid out the list of sins involved and concluded, “Facebook didn’t know how to work its own privacy settings for investors. It couldn’t figure out, essentially, who should know what.” Reuters’ Felix Salmon was more specific with his list of incompetents, Cephalexin for sale, declaring that the only winners in this game were the ones who didn’t play at all. The Big Picture’s Barry Ritholtz also ripped apart the debacle Cephalexin Dosage, .

The whole scandal still leaves open the question of what Facebook should, in fact, be valued at. At Technology Review, Michael Wolff was most provocative with his assessment, Cephalexin without a prescription, arguing that Facebook is just another business inextricably reliant on a fatally flawed online advertising model: “The crash will come. And Facebook—that putative transformer of worlds, which is, in reality, only an ad-driven site—will fall with everybody else,” he wrote. Harvard’s Doc Searls echoed Wolff’s thoughts about the brokenness of Facebook’s (and the web’s) ad model, and media consultant Terry Heaton countered that the broken industry isn’t the ad-supported web, Cephalexin reviews, but Madison Avenue’s insistence on the status quo on that web.

Others looked more closely at the future of Facebook’s services and of the social web more generally, Cephalexin Dosage. The Atlantic’s Alexis Madrigal wondered whether Facebook’s users would keep sharing and what would become of its native and mobile users, and ReadWriteWeb’s Dan Frommer examined the company’s four biggest risks (there’s mobile and advertising again!). There were other problems spotted: All Things D’s Peter Kafka looked at the continued decline of Facebook’s Social Reader apps, and The New York Times’ Nick Bilton contrasted Facebook and Twitter’s approaches to privacy. Tech blogger Dave Winer insisted that we can do better than Facebook, What is Cephalexin, while Slate’s Farhad Manjoo contended that Facebook has improved Silicon Valley.

 

The end of an era for New Orleans news: The American newspaper industry absorbed another big blow this week when the New Orleans Times-Picayune announced that it would drop back from daily publication to just three days a week, a change accompanied by the creation of a new corporate entity to run the paper and heavy layoffs — possibly a third of the newsroom. Cephalexin Dosage, The change will leave New Orleans as the largest city in the U.S. without a daily newspaper.

The news was broken by The New York Times’ David Carr, and according to the New Orleans alt-weekly Gambit, Times-Picayune employees learned of the paper’s fate through his report. (They later got this memo from the paper’s publisher.) All this came despite the fact that, Cephalexin schedule, as Jim Romenesko reported, the paper remains profitable. For some of the background on the paper — which is owned by Advance Publications, a division of the Newhouse publishing empire — see this post at the Columbia Journalism Review. (Advance also announced they’d be doing the same thing with three of its Alabama papers, led by the Birmingham News.)

Media analyst Ken Doctor has an extremely useful analysis of what exactly Advance/Newhouse is trying to accomplish with this move, and what perils it faces, Cephalexin Dosage. Doctor called the paper’s transition to digital a “forced march” because the paper simply isn’t ready for a digital transformation, particularly in terms of digital circulation. Purchase Cephalexin online, Others were similarly skeptical: The immediate comparison was to Advance’s 2009 transition of the daily Ann Arbor News to AnnArbor.com, and Forbes’ Micheline Maynard gave a bleak picture of what’s left of that news organization and the hole it’s left in the community.

Forbes’ John McQuaid, a former Times-Picayune reporter, described the way Advance’s web strategy has been “only lightly tethered to newsgathering,” and concluded that “with Advance, news has always been an adjunct to its vanilla branded sites, not something that is driving the internal business conversation, Cephalexin samples, and it shows.” And former Wall Street Journal writer (and Times-Picayune intern) Jason Fry said he doesn’t see any reason for optimism that Advance will get the web right in this case.

Free Press’ Josh Stearns noted that while the future-of-news world has been optimistically focused on experiments to sustain quality journalism in certain hubs like San Francisco, Chicago, and New York, they need to pay closer attention to mid-sized cities like New Orleans, where the infrastructure simply isn’t there to pick up the journalism being cut at major traditional news organizations.

—

What’s behind Buffett’s newspaper buy?: I briefly mentioned Warren Buffett’s purchase Cephalexin Dosage,  late last week of 63 newspapers from Media General in last week’s review, but some smart commentary has come out about the deal since then (along with a few other pieces I missed at the time), so it’s worth touching on again. Cephalexin long term, Media analyst Ken Doctor did a sharp rundown of the deal, pointing out that the upside of Media General’s broadcast properties and the real estate involved with the newspapers Buffett’s buying should help buffer him from the inherent danger of buying a set of newspapers. Reuters’ Jack Shafer pointed out several of Buffett’s past bearish statements about newspapers, but said he’s most likely buying because he sees an undervalued asset, not for any sentimental reason.

The Columbia Journalism Review’s Justin Peters and The Washington Post’s Erik Wemple both explained why these papers might be surprisingly valuable for Buffett: While major metro dailies have taken a beating, smaller community newspapers in rural areas have weathered the digital storm fairly well so far, in part because of their monopoly on local news and the slower rates of broadband adoption there, online buy Cephalexin without a prescription.

Former journalism professor Philip Meyer made a similar point, arguing that Buffett is the type of buyer who’s happy with the new normal of lower profit margins for newspapers: “It looks like he is betting that the slide in newspaper earning power has leveled out. The Internet has done all the damage it can, and papers still make money.” PaidContent’s Jeff John Roberts looked at the economic sense Buffett’s paywall plan makes, while media consultant Dan Conover said he should be open to other non-paywall-based models, Cephalexin Dosage. Poynter’s Andrew Beaujon, meanwhile, said we may be ignoring another big reason for news org purchases like Buffett’s — they’re a platform for personal philosophies of how journalism should be done. Buffett did tell his new papers’ publishers that he would be hands-off with them, Cephalexin dosage, and that he expected to buy more small and mid-sized papers.

A dubious bid to outlaw anonymous comments: This bill is almost too ridiculous to merit an item, but I’ll give it a quick mention here anyway. New York lawmakers have proposed state legislation that would make anonymous comments illegal — New York-based blogs and websites would have to add a name to posts or delete them. Cephalexin Dosage, Wired’s David Kravets, who brought the bill to national attention this week, pointed out that there was no identification required of those requesting such post takedowns.

The bill, which was supposedly meant as a weapon against cyber-bullying and attacks against “local businesses and elected officials,” was predictably (and rightly) met with derision from scholars and those on the web. Columbia’s Tim Wu told The Guardian the bill was “an obvious first amendment violation, Cephalexin blogs,” and the bill was also ripped at sites like Techdirt and Animal. BetaBeat reported that some of the lawmakers involved with the bill were surprised by the blowback about it, while The Atlantic brought out a dissenting opinion, with a point/counterpoint on the value of anonymous online discourse.

Reading roundup: Plenty of other stuff going during this week of Facebook:

— The Wall Street Journal reported on some of the ongoing struggles with AOL’s hyperlocal journalism project, Patch, Comprar en línea Cephalexin, comprar Cephalexin baratos, breaking the news that 20 Patch employees were being laid off and that one of AOL’s major investors is trying to get Patch killed, sold, or put into a joint venture. Jeff Bercovici of Forbes said it’s going to take a lot more cost-cutting or revenue-raising to get Patch to profitability by next year, and The Washington Post’s Erik Wemple said hyperlocal journalism’s business model doesn’t have room for executives in suits, Cephalexin Dosage.

— The New York Times’ public editor, Arthur Brisbane, will leave his position in September after two years, declining an optional third year. The Washington Post’s Erik Wemple, Cephalexin from canadian pharmacy, who broke the story, took the opportunity to criticize his most recent column, and Poynter’s Craig Silverman proposed five qualifications for the next public editor of the Times. Poynter also held a chat about the role of ombudsmen with Washington Post ombudsman Patrick Pexton and Reuters’ Jack Shafer.

— This week in Murdoch was a relatively quiet one. Cephalexin Dosage, News Corp. was reported to be considering spinning off its British newspapers — the Sun, the Times, and the Sunday Times — in order to preserve the rest of its media empire, something Murdoch denied but the Columbia Journalism Review’s Emily Bell saw as quite sensible. Here at the Lab, Ken Doctor examined what a trust for those papers might look like.

— A couple of interesting pieces of survey data discussed this week: The study that drew most of the headlines was one that looked at the political knowledge of audiences for various news outlets, finding NPR’s listeners to be the most informed and Fox News’ viewers to be the least informed. Another study found that about half of media professionals abandon websites when they hit a paywall.

— Finally, a couple of cool pieces on data journalism — Simon Rogers of The Guardian urged us to take on the punk “anyone can do it” mindset toward data journalism, and Alex Howard of O’Reilly Radar talked with former Guardian digital editor Emily Bell about her efforts to put data journalism into action with students at Columbia University.

Similar posts: Synthroid Dosage. Cipro For Sale. Cipro Dosage. Cheap Zoloft. Generic Bactrim. Real brand Cipro online.
Trackbacks from: Cephalexin Dosage. Cephalexin Dosage. Cephalexin Dosage. Cephalexin from canada. Cephalexin wiki. No prescription Cephalexin online.